Boston Scientific Corporation $BSX Holdings Lessened by Curated Wealth Partners LLC

Key Points

• Curated Wealth Partners cut its Boston Scientific stake by 97.7% in the third quarter, selling 598,352 shares and retaining 14,347 shares worth approximately $626,000. Institutional investors and hedge funds collectively own 89.07% of the company.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $68.23, despite several firms lowering their targets.
• Boston Scientific insiders purchased about $9.4 million of stock over the past 90 days, including a roughly $9 million purchase by CEO Michael Mahoney. The company also exceeded quarterly earnings and revenue expectations, reporting $0.86 EPS and $5.44 billion in revenue.

Curated Wealth Partners LLC reduced its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 97.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,347 shares of the medical equipment provider's stock after selling 598,352 shares during the period. Curated Wealth Partners LLC's holdings in Boston Scientific were worth $626,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the 1st quarter valued at $28,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Boston Scientific in the first quarter worth $32,000. Measured Wealth Private Client Group LLC increased its position in shares of Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider's stock worth $34,000 after purchasing an additional 387 shares during the period. Kelleher Financial Advisors acquired a new position in Boston Scientific in the second quarter valued at about $25,000. Finally, Nvwm LLC raised its stake in Boston Scientific by 526.2% in the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 542 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BSX shares. Argus reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Royal Bank Of Canada decreased their target price on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, July 30th. Truist Financial decreased their target price on shares of Boston Scientific from $57.00 to $51.00 and set a "buy" rating on the stock in a research note on Wednesday. Rothschild & Co Redburn lowered their price target on shares of Boston Scientific from $106.00 to $78.00 and set a "buy" rating for the company in a report on Thursday, July 30th. Finally, Oppenheimer dropped their price target on Boston Scientific from $85.00 to $65.00 and set an "outperform" rating for the company in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $68.23.

Insiders Place Their Bets

In other Boston Scientific news, Director David Habiger bought 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares of the company's stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $44.17 on Friday. The stock has a market cap of $64.02 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.04 and a beta of 0.58. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock's 50-day moving average is $46.16 and its 200-day moving average is $49.80. Boston Scientific Corporation has a 1-year low of $41.38 and a 1-year high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The firm's revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.24 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.